Villanueva G R, Mendoza M E, el-Mir M Y, Monte M J, Herrera M C, Marin J J
Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, Spain.
Pharmacol Toxicol. 1997 Mar;80(3):111-7. doi: 10.1111/j.1600-0773.1997.tb00382.x.
The liver and kidney collaborate in the excretion of the cytostatic drug, cis-diamminedichloroplatinum(II) (cisplatin) from the body. Enhancement of this process is envisaged as a way of reducing cisplatin toxicity, thus allowing increases in the doses administered. In this sense, using different compounds, several attempts have been made to enhance cisplatin biliary excretion. In this study, the ability of endogenous compounds belonging to the bile acid family to improve cisplatin excretion by the isolated perfused rat liver was investigated. A highly choleretic bile acid (ursodexoycholic acid) and two others bile acids with marked micelle-forming properties (glycocholic acid and chenodeoxycholic acid) were chosen for study. When these drugs were given at concentrations (1 microM) that did not affect the viability of liver preparations, a correlation between the biliary excretion of platinum and bile acid output was found. This was not due to the incorporation of cisplatin into mixed micelles because no correlation between the biliary output of lecithin or cholesterol and platinum was observed. Moreover, a wash-out effect of bile acids was probably not the cause of bile acid-induced platinum output into bile because no correlation between this and bile flow was found. An enhancement in cisplatin transport processes by the hepatocyte or by direct binding of cisplatin to bile acid monomers or aggregates cannot be ruled out. In spite of the biliary induction of cisplatin output, the net excretion of platinum was reduced under bile acid administration. This was related to lower platinum contents in the liver tissue, probably due to an inhibition of the ability of the hepatocyte to take up and/or retain cisplatin while subject to bile acid infusion. In summary, our results indicate that bile acids reduce the net excretion of cisplatin by the liver even though they induce an enhancement in the transport of this compound from the hepatocyte into bile.
肝脏和肾脏协同作用,将细胞毒性药物顺二氨二氯铂(II)(顺铂)排出体外。增强这一过程被设想为降低顺铂毒性的一种方法,从而允许增加给药剂量。从这个意义上说,人们已经尝试使用不同的化合物来增强顺铂的胆汁排泄。在本研究中,研究了胆汁酸家族中的内源性化合物通过离体灌注大鼠肝脏改善顺铂排泄的能力。选择了一种高度利胆的胆汁酸(熊去氧胆酸)和另外两种具有显著形成胶束特性的胆汁酸(甘氨胆酸和鹅去氧胆酸)进行研究。当以不影响肝脏制剂活力的浓度(1微摩尔)给予这些药物时,发现铂的胆汁排泄与胆汁酸输出之间存在相关性。这不是由于顺铂掺入混合胶束,因为未观察到卵磷脂或胆固醇的胆汁输出与铂之间的相关性。此外,胆汁酸的洗脱效应可能不是胆汁酸诱导铂排入胆汁的原因,因为未发现这与胆汁流量之间的相关性。不能排除肝细胞增强顺铂转运过程或顺铂直接与胆汁酸单体或聚集体结合的可能性。尽管胆汁酸诱导了顺铂的排出,但在给予胆汁酸的情况下,铂的净排泄量减少。这与肝组织中较低的铂含量有关,可能是由于在输注胆汁酸时,肝细胞摄取和/或保留顺铂的能力受到抑制。总之,我们的结果表明,胆汁酸降低了肝脏对顺铂的净排泄,尽管它们增强了这种化合物从肝细胞向胆汁的转运。